RECORA- Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy

Trial Profile

RECORA- Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2018

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms RECORA
  • Sponsors Bayer
  • Most Recent Events

    • 20 Jan 2018 Results of a final analysis presented at the 2018 Gastrointestinal Cancers Symposium
    • 17 Jan 2018 According to a Bayer media release, data will be present at the American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancer Symposium 2018.
    • 30 Aug 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top